The ODYSSEY OUTCOMES trial recently observed that alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor used in the treatment of hypercholesterolaemia, could reduce both future type 1 and type 2 myocardial infarction by 13% and 22%, respectively, as compared to placebo.31 The gene discussed is PCSK9; the disease is Hypercholesterolemia.